Levoin N, Labeeuw O, Calmels T, Poupardin-Olivier O, Berrebi-Bertrand I, Lecomte JM, Schwartz JC, Capet M. Homology Model Versus X-ray Structure in Receptor-based Drug Design: A Retrospective Analysis with the Dopamine D3 Receptor. Levoin N, Calmels T, Krief S, Danvy D, Berrebi-Bertrand I, Lecomte JM, Schwartz JC, Capet M. Bioorganic & Medicinal Chemistry Letters. Part 3: an alcohol function to improve the pharmacokinetic profile. Novel and highly potent histamine H3 receptor ligands. Labeeuw O, Levoin N, Poupardin-Olivier O, Calmels T, Ligneau X, Berrebi-Bertrand I, Robert P, Lecomte JM, Schwartz JC, Capet M. Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant BF2.649) in epilepsy: dose-dependent effects in the human photosensitivity model. Kasteleijn-Nolst Trenité D, Parain D, Genton P, Masnou P, Schwartz JC, Hirsch E. Determination of the binding mode and interacting amino-acids for dibasic H3 receptor antagonists. Levoin N, Labeeuw O, Krief S, Calmels T, Poupardin-Olivier O, Berrebi-Bertrand I, Lecomte JM, Schwartz JC, Capet M. The Journal of Allergy and Clinical Immunology. Ambient air pollution, lung function, and airway responsiveness in asthmatic children. ![]() Ierodiakonou D, Zanobetti A, Coull BA, Melly S, Postma DS, Boezen HM, Vonk JM, Williams PV, Shapiro GG, McKone EF, Hallstrand TS, Koenig JQ, Schildcrout JS, Lumley T, Fuhlbrigge AN. Improving selectivity of dopamine D3 receptor ligands. PMID 27060410 DOI: 10.1016/J.Neuropharm.2016.04.006Ĭapet M, Calmels T, Levoin N, Danvy D, Berrebi-Bertrand I, Stark H, Schwartz JC, Lecomte JM. Clinical trials with H3-receptor inverse agonists: what they tell us about the role of histamine in the human brain. Synthesis and evaluation of a 2-benzothiazolylphenylmethyl ether class of histamine H4 receptor antagonists. Labeeuw O, Levoin N, Billot X, Danvy D, Calmels T, Krief S, Ligneau X, Berrebi-Bertrand I, Robert P, Lecomte JM, Schwartz JC, Capet M. Discovery of nanomolar ligands with novel scaffolds for the histamine H4 receptor by virtual screening. Levoin N, Labeeuw O, Billot X, Calmels T, Danvy D, Krief S, Berrebi-Bertrand I, Lecomte JM, Schwartz JC, Capet M. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM, Schwartz JC. 0624 Anticataplectic Efficacy of Pitolisant, the First Potent and Highly Selective Histamine H3-Receptor Antagonist/Inverse Agonist Sleep. Thorpy M, Schwartz J, Lecomte J, Caussé C, Dayno JM. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study. PMID 31626696 DOI: 10.1093/Sleep/Zsz252ĭauvilliers Y, Arnulf I, Szakacs Z, Leu-Semenescu S, Lecomte I, Scart-Gres C, Lecomte JM, Schwartz JC. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Setnik B, McDonnell M, Mills C, Scart-Grès C, Robert P, Dayno JM, Schwartz JC. Pharmacokinetics of pitolisant in children and adolescents with narcolepsy. ![]() Lecendreux M, Plazzi G, Franco P, Jacqz-Aigrain E, Robert P, Duvauchelle T, Schwartz JC. Exploring Occupancy of the Histamine H3 Receptor by Pitolisant in Humans Using Positron Emission Tomography. Rusjan PM, Sabioni P, Di Ciano P, Mansouri E, Boileau I, Laveillé A, Capet M, Duvauchelle T, Schwartz JC, Robert P, Le Foll B.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |